2026 Dealmakers' Intentions Survey

The 2026 Syneos Health® Dealmakers’ Intentions Survey captures how biopharmaceutical executives are positioning their deal strategies amid a market that is stabilizing but far from settled.  For this report, the 16^th year in the series, a total of 150 senior-level industry decision makers globally offered their candid views on: 

• The volume and nature of deals expected in 2026; 

• Supply and demand expectations for assets by therapeutic area and stage of development; 

• The importance dealmakers are assigning to various advanced technologies; and 

• How tariffs, trade restrictions and most favored nation status may impact dealmaking in the year ahead.  

Collectively, the 2026 survey results depict a dealmaking market that is functioning, disciplined and increasingly strategic—where clarity of value proposition, asset differentiation and alignment with evolving external realities are central to transaction success.